SG11201605539SA - Hydroxy formamide derivatives and their use - Google Patents
Hydroxy formamide derivatives and their useInfo
- Publication number
- SG11201605539SA SG11201605539SA SG11201605539SA SG11201605539SA SG11201605539SA SG 11201605539S A SG11201605539S A SG 11201605539SA SG 11201605539S A SG11201605539S A SG 11201605539SA SG 11201605539S A SG11201605539S A SG 11201605539SA SG 11201605539S A SG11201605539S A SG 11201605539SA
- Authority
- SG
- Singapore
- Prior art keywords
- formamide derivatives
- hydroxy formamide
- hydroxy
- derivatives
- formamide
- Prior art date
Links
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925848P | 2014-01-10 | 2014-01-10 | |
PCT/IB2015/050179 WO2015104684A1 (fr) | 2014-01-10 | 2015-01-09 | Dérivés d'hydroxy formamide et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605539SA true SG11201605539SA (en) | 2016-08-30 |
Family
ID=52440747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605539SA SG11201605539SA (en) | 2014-01-10 | 2015-01-09 | Hydroxy formamide derivatives and their use |
Country Status (21)
Country | Link |
---|---|
US (2) | US10450288B2 (fr) |
EP (1) | EP3092233A1 (fr) |
JP (2) | JP2017507915A (fr) |
KR (1) | KR20160106684A (fr) |
CN (2) | CN109970797A (fr) |
AU (1) | AU2015205370B2 (fr) |
BR (1) | BR112016016130A2 (fr) |
CA (1) | CA2936467A1 (fr) |
CL (1) | CL2016001746A1 (fr) |
CR (1) | CR20160316A (fr) |
DO (1) | DOP2016000170A (fr) |
EA (1) | EA031654B1 (fr) |
IL (1) | IL246653A0 (fr) |
MA (1) | MA39171A1 (fr) |
MX (1) | MX2016009064A (fr) |
PE (1) | PE20160998A1 (fr) |
PH (1) | PH12016501349A1 (fr) |
SG (1) | SG11201605539SA (fr) |
TW (1) | TW201620887A (fr) |
UA (1) | UA118278C2 (fr) |
WO (1) | WO2015104684A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160106684A (ko) * | 2014-01-10 | 2016-09-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 히드록시포름아미드 유도체 및 그의 용도 |
WO2017006295A1 (fr) * | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés d'hydroxy formamide et leur utilisation |
JP2018525353A (ja) | 2015-07-09 | 2018-09-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Bmp1、tll1および/またはtll2の阻害剤としての使用するための、n−ヒドロキシホルムアミド化合物およびそれらを含んでなる組成物 |
CN106699604B (zh) * | 2017-01-09 | 2019-01-01 | 四川同晟生物医药有限公司 | 一种沙库比曲及其中间体的制备方法 |
US9862675B1 (en) * | 2017-07-05 | 2018-01-09 | King Fahd University Of Petroleum And Minerals | Method of N-formylating amines with a phosphonic anhydride |
EP4225321A1 (fr) * | 2020-10-07 | 2023-08-16 | Venatorx Pharmaceuticals, Inc. | Procédé pour composés contenant du bore |
CN114195638B (zh) * | 2021-12-28 | 2023-07-14 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的制备方法 |
CN114230463B (zh) * | 2021-12-28 | 2024-06-21 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的后处理方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228982B1 (en) | 1992-05-22 | 2001-05-08 | Benget Norden | Double-stranded peptide nucleic acids |
US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US6451968B1 (en) | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
GB9311386D0 (en) | 1993-06-02 | 1993-07-21 | Pna Diagnostics As | Nucleic acid analogue assay procedures |
GB2285445A (en) | 1993-12-06 | 1995-07-12 | Pna Diagnostics As | Protecting nucleic acids and methods of analysis |
GB2289677A (en) | 1993-12-06 | 1995-11-29 | Pna Diagnostics As | Labelling of nucleic acid analogue-peptide chimerae |
WO1996011205A1 (fr) | 1994-10-06 | 1996-04-18 | Isis Pharmaceuticals, Inc. | Conjugues d'acides nucleiques peptidiques |
BR9709370A (pt) | 1996-05-30 | 1999-10-05 | Wisconsin Alumni Res Found | Gene semelhante a tolóide de mamìfero e proteìna. |
US6008017A (en) | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
US6037139A (en) | 1997-06-03 | 2000-03-14 | Wisconsin Alumni Research Foundation | System for assaying modulators of procollagen maturation |
DE19726427A1 (de) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
EP0922702A1 (fr) | 1997-12-13 | 1999-06-16 | Roche Diagnostics GmbH | Dérivés de l'azulène et compositions pharmaceutiques les contenant |
WO1999051730A2 (fr) | 1998-04-03 | 1999-10-14 | Wisconsin Alumni Research Foundation | Gene et proteine de mammifere de type tolloide |
DE19850072A1 (de) * | 1998-10-30 | 2000-05-04 | Bayer Ag | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
CA2352740A1 (fr) * | 1998-12-10 | 2000-06-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de la c-proteinase de procollagene |
TR200101868T2 (tr) | 1998-12-22 | 2001-11-21 | F. Hoffmann-La Roche Ag | Sülfonamit hidroksamatlar. |
WO2001016322A2 (fr) | 1999-09-01 | 2001-03-08 | Subsidiary No. 3, Inc. | Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains |
WO2001016323A2 (fr) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions et procedes d'inhibition de l'infection due au virus de l'immunodeficience humaine a l'aide de genes cellulaires humains a regulation negative |
GB9930570D0 (en) | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU2001268422A1 (en) | 2000-06-15 | 2001-12-24 | University Of Kentucky Research Foundation | Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders |
JP2004509941A (ja) | 2000-09-29 | 2004-04-02 | プロリフィクス リミテッド | Hdacインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
US20050147602A1 (en) | 2000-10-19 | 2005-07-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix |
US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
GB0031321D0 (en) | 2000-12-21 | 2001-02-07 | Pfizer Ltd | Treatment |
US6821972B2 (en) * | 2001-03-30 | 2004-11-23 | Pfizer Inc. | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
GB0108097D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
US20030087273A1 (en) | 2001-06-29 | 2003-05-08 | Holzmayer Tanya A. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
DE10134243A1 (de) | 2001-07-14 | 2003-03-27 | Burchardt Elmar Reinhold | Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen |
ATE389638T1 (de) | 2001-11-01 | 2008-04-15 | Janssen Pharmaceutica Nv | Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3- |
AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
US20050261283A1 (en) | 2002-05-13 | 2005-11-24 | Vikas Sukhatme | Methods and compositions for the treatment of graft failure |
DE60331778D1 (de) | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
ES2390767T3 (es) * | 2002-12-11 | 2012-11-16 | Glaxosmithkline Llc | Inhibidores de la péptido desformilasa |
US20060240014A1 (en) | 2003-06-03 | 2006-10-26 | Beth Israel Deaconess Medical Center | Methods and compounds for the treatment of vascular stenosis |
US7332485B2 (en) | 2003-07-08 | 2008-02-19 | Smithkline Beecham Corp | Peptide deformylase inhibitors |
EP1701729B1 (fr) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Compositions de matrice osseuse ameliorees et methodes associees |
WO2006057951A2 (fr) | 2004-11-22 | 2006-06-01 | Beth Israel Deaconess Medical Center | Procedes et compositions de traitement d'echec de greffe |
DK1828160T3 (da) * | 2004-12-21 | 2012-02-13 | Merck Serono Sa | Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere |
US20090305963A1 (en) | 2005-01-19 | 2009-12-10 | Sukhatme Vikas P | Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis |
WO2007006858A2 (fr) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Methode de traitement de maladies cardio-vasculaires et du metabolisme et detection des risques associes |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
CA2630551C (fr) | 2005-11-24 | 2014-08-05 | Laboratoires Serono S.A. | Derives de n-hydroxamides et leurs applications |
CA2829865A1 (fr) | 2006-07-21 | 2008-01-24 | Genera Istrazivanja D.O.O. | Procollagene c-proteinase liee a la bmp-1, destinee au diagnostic et au traitement des defauts et des affections des os et des tissus mous |
WO2008024767A2 (fr) | 2006-08-21 | 2008-02-28 | Wisconsin Alumni Research Foundation | Procédé et composition permettant de traiter un trouble fibrotique |
EP1932907A1 (fr) | 2006-12-12 | 2008-06-18 | Novartis AG | Structure cristalline du domaine catalytique de protéase 1 de type tolloïde et ses utilisations |
US20090076062A1 (en) | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
WO2009097893A1 (fr) | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Procédés de traitement d'une maladie cardiaque associée à une fibrose myocardique à l'aide d'un inhibiteur de pcp |
EP2949752B1 (fr) | 2008-09-22 | 2017-12-20 | RXi Pharmaceuticals Corporation | Composés d'arni de taille réduite à auto-délivrance |
US20110293526A1 (en) | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
US8895497B2 (en) | 2009-12-04 | 2014-11-25 | Dcb-Usa, Llc | Cathepsin S inhibitors |
WO2013163479A1 (fr) | 2012-04-25 | 2013-10-31 | General Istrazivanja D.O.O. | Méthodes et compositions de traitement et de diagnostic de l'infarctus aigu du myocarde |
KR20160106684A (ko) * | 2014-01-10 | 2016-09-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 히드록시포름아미드 유도체 및 그의 용도 |
WO2017006295A1 (fr) | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés d'hydroxy formamide et leur utilisation |
JP2018525353A (ja) | 2015-07-09 | 2018-09-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Bmp1、tll1および/またはtll2の阻害剤としての使用するための、n−ヒドロキシホルムアミド化合物およびそれらを含んでなる組成物 |
-
2015
- 2015-01-09 KR KR1020167021496A patent/KR20160106684A/ko not_active Application Discontinuation
- 2015-01-09 EA EA201691412A patent/EA031654B1/ru not_active IP Right Cessation
- 2015-01-09 SG SG11201605539SA patent/SG11201605539SA/en unknown
- 2015-01-09 WO PCT/IB2015/050179 patent/WO2015104684A1/fr active Application Filing
- 2015-01-09 UA UAA201608690A patent/UA118278C2/uk unknown
- 2015-01-09 CN CN201910119933.5A patent/CN109970797A/zh active Pending
- 2015-01-09 JP JP2016545920A patent/JP2017507915A/ja not_active Ceased
- 2015-01-09 MX MX2016009064A patent/MX2016009064A/es unknown
- 2015-01-09 CR CR20160316A patent/CR20160316A/es unknown
- 2015-01-09 EP EP15702008.2A patent/EP3092233A1/fr not_active Withdrawn
- 2015-01-09 CN CN201580013152.8A patent/CN106103431B/zh not_active Expired - Fee Related
- 2015-01-09 US US15/110,776 patent/US10450288B2/en not_active Expired - Fee Related
- 2015-01-09 AU AU2015205370A patent/AU2015205370B2/en not_active Ceased
- 2015-01-09 CA CA2936467A patent/CA2936467A1/fr not_active Abandoned
- 2015-01-09 MA MA39171A patent/MA39171A1/fr unknown
- 2015-01-09 TW TW104100718A patent/TW201620887A/zh unknown
- 2015-01-09 BR BR112016016130A patent/BR112016016130A2/pt not_active Application Discontinuation
- 2015-01-09 PE PE2016001113A patent/PE20160998A1/es unknown
-
2016
- 2016-07-07 CL CL2016001746A patent/CL2016001746A1/es unknown
- 2016-07-07 IL IL246653A patent/IL246653A0/en unknown
- 2016-07-07 PH PH12016501349A patent/PH12016501349A1/en unknown
- 2016-07-08 DO DO2016000170A patent/DOP2016000170A/es unknown
-
2019
- 2019-09-03 JP JP2019160658A patent/JP2020011968A/ja active Pending
- 2019-10-17 US US16/655,784 patent/US20200095217A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN106103431A (zh) | 2016-11-09 |
UA118278C2 (uk) | 2018-12-26 |
CA2936467A1 (fr) | 2015-07-16 |
CR20160316A (es) | 2016-09-19 |
US20200095217A1 (en) | 2020-03-26 |
AU2015205370A1 (en) | 2016-07-21 |
CN109970797A (zh) | 2019-07-05 |
EA201691412A1 (ru) | 2016-12-30 |
BR112016016130A2 (pt) | 2017-08-08 |
PH12016501349A1 (en) | 2016-08-15 |
MX2016009064A (es) | 2017-01-23 |
JP2020011968A (ja) | 2020-01-23 |
AU2015205370B2 (en) | 2017-11-30 |
KR20160106684A (ko) | 2016-09-12 |
WO2015104684A1 (fr) | 2015-07-16 |
DOP2016000170A (es) | 2016-10-30 |
IL246653A0 (en) | 2016-08-31 |
EA031654B1 (ru) | 2019-02-28 |
EP3092233A1 (fr) | 2016-11-16 |
US20160340328A1 (en) | 2016-11-24 |
CN106103431B (zh) | 2019-03-15 |
MA39171A1 (fr) | 2017-07-31 |
US10450288B2 (en) | 2019-10-22 |
PE20160998A1 (es) | 2016-10-26 |
TW201620887A (zh) | 2016-06-16 |
JP2017507915A (ja) | 2017-03-23 |
CL2016001746A1 (es) | 2017-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258081B (en) | Benzimidazole history and their use | |
IL247252B (en) | History of isoquinoline and its use | |
HK1231471A1 (zh) | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 | |
IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
HK1246156B (zh) | Fgf21衍生物及其用途 | |
EP3154972A4 (fr) | Dérivés d'azamophinan et leur utilisation | |
GB201401617D0 (en) | Novel combination and use | |
IL264813B (en) | 2-oxo-imidazopyridines and their use | |
IL252560B (en) | Heterocyclic derivatives and their uses | |
IL246653A0 (en) | History of hydroxyformamide and their use | |
SG11201609490QA (en) | Polymer-flavonoid conjugate and uses thereof | |
SG11201608943VA (en) | Substituted 4-phenylpiperidines, their preparaiton and use | |
HK1243950A1 (zh) | 新型組合物和用途 | |
HK1243077A1 (zh) | 呱啶基吡唑並嘧啶酮及其用途 | |
EP3174475C0 (fr) | Dispositifs de cathéter et kits | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
HK1232211A1 (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
GB201408091D0 (en) | Methods and uses | |
SG10201505749YA (en) | Urinal apparatus and urinal unit | |
PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
GB201416073D0 (en) | Methods and uses | |
GB201416086D0 (en) | Methods and uses |